Back to Search
Start Over
PARP inhibitors in metastatic prostate cancer.
- Source :
-
Frontiers in oncology [Front Oncol] 2023 Apr 24; Vol. 13, pp. 1159557. Date of Electronic Publication: 2023 Apr 24 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Poly-ADP ribose polymerase inhibitors (PARPi) are an emerging therapeutic option for the treatment of prostate cancer. Their primary mechanism of action is via induction of synthetic lethality in cells with underlying deficiencies in homologous recombination repair (HRR). In men with metastatic castrate-resistant prostate cancer (mCRPC) and select HRR pathway alterations, PARPi treatment has been shown to induce objective tumor responses as well as improve progression free and overall survival. Presently, there are two PARPi, olaparib and rucaparib, that are FDA approved in the treatment of mCRPC. Ongoing research is focused on identifying which HRR alterations are best suited to predict response to PARPi so that these therapies can be most effectively utilized in the clinic. While resistance to PARPi remains a concern, combination therapies may represent a mechanism to overcome or delay resistance.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Taylor, Kosoff, Emamekhoo, Lang and Kyriakopoulos.)
Details
- Language :
- English
- ISSN :
- 2234-943X
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- Frontiers in oncology
- Publication Type :
- Academic Journal
- Accession number :
- 37168382
- Full Text :
- https://doi.org/10.3389/fonc.2023.1159557